『2 Minutes with Joey - LLY Stock News』のカバーアート

2 Minutes with Joey - LLY Stock News

2 Minutes with Joey - LLY Stock News

著者： 2 Minutes with Joey
無料で聴く

Two minutes with Joey on Eli Lilly (LLY) - a quick daily recap of what the stock did today and why, in plain English. Information and entertainment only, not financial advice.Copyright 2 Minutes with Joey 社会科学
エピソード
  • LLY Today - Aug 13: Lawsuits Weigh on Stock

    LLY Today - Aug 13: Lawsuits Weigh on Stock
    2026/08/13
    Hey there! It’s Joey here, your go-to guy for stock talk. I’ve been in the investing game for a while, and today, we’re looking at Eli Lilly, or LLY for short. Today was a bit of a rough one for them—stock dipped just a tiny bit, down 0.03%. Not a huge drop, but still a red day.

    So, what’s the deal? Eli Lilly had some news that didn’t sit well with investors. They’ve got ongoing lawsuits related to their obesity drug, Retatrutide, which is causing some worries for folks who are keeping an eye on the stock. People hit the sell button pretty quickly when they heard about it. You know how it goes—lawsuits can freak investors out, and this one seems to be doing just that.

    Now, on the flip side, there was some chatter about how Eli Lilly is still a strong company, and their market share is looking good. Like, they’re making moves to grab access to new markets, which could mean more customers down the line. But that lawsuit news definitely overshadowed the positives today.

    And speaking of the competition, Novo Nordisk’s CEO is out there defending their lawsuit against Eli Lilly, saying competition needs to be fair. Seems like there’s a lot of back-and-forth going on in the obesity drug space. It’s wild—these companies are really going at it, trying to stake their claim.

    One quick thing to keep in mind: Eli Lilly is still being watched closely by analysts, even with the stock slipping a bit. They’re considered one of the top stocks in the IBD 50, so there’s still a lot of interest in how they’ll perform moving forward.

    Alright, that’s a wrap for today! Just remember, this is all for fun and info—no buy or sell advice here. Thanks for tuning in, and catch you next time!
    続きを読む 一部表示
    2 分
  • LLY Today - Aug 12: Weight Loss Pill Approval

    LLY Today - Aug 12: Weight Loss Pill Approval
    2026/08/12
    Hey there! It’s Joey here, your friendly neighborhood investor, breaking down today’s market action. We’re talking about Eli Lilly, and today was a red day for them, down just about 0.81%.

    So, what went down? The stock slipped a bit, and it wasn’t a huge surprise. It seems like investors were feeling a little jittery today. There were some mixed signals in the market, and Eli Lilly didn’t exactly stand out among its peers. It’s like they were just kind of there while others were making moves.

    Now, why’d this happen? Well, part of the chatter was about their weight loss pill snagging its first approval in Europe. That’s a win, right? But instead of rallying off that good news, the stock still took a hit. It looks like broader market pressures, like oil prices dragging things down, played a role too. So, while there’s positive momentum with that approval, it wasn’t enough to keep the stock from getting a little beat up today.

    Also, there’s been some buzz from analysts after Eli Lilly's recent Q2 earnings call. They had some tough questions, and it seems like investors are still digesting what that all means for the company moving forward. So, yeah, it’s a bit of a mixed bag right now.

    Looking ahead, Eli Lilly’s got their eyes on growth, especially with their new weight loss pill making waves in Europe. That’s something to keep an eye on as they push for more approvals and market expansions.

    Alright, that’s a wrap for today! Just remember, I’m here to share info and keep it fun, but this isn’t financial advice. Catch you later, and happy investing!
    続きを読む 一部表示
    1 分
  • LLY Today - Aug 11: Earnings Anticipation

    LLY Today - Aug 11: Earnings Anticipation
    2026/08/11
    Hey there! It’s Joey here, your friendly neighborhood investor. Just hanging out, breaking down the day for you. Today we're talking about Eli Lilly, and it was a bit of a red day for them. The stock dipped about 1%—not huge, but still a bummer.

    So, what went down? Well, LLY started the day with some solid energy, but as the hours rolled on, it got a bit of a slow bleed. People were probably feeling the jitters ahead of earnings coming up soon. You know how that goes—everyone gets a little anxious when big numbers are about to drop.

    Now, let’s chat about the why. Analysts have been buzzing about Eli Lilly lately, especially with the whole GLP-1 market thing. There’s been some chatter about how their drugs are really changing the game. Some analysts even bumped up their fair value estimates for the stock. But still, with earnings around the corner, folks are a little cautious, and that makes sense. Nobody wants to get burned if things don’t pan out as expected.

    And speaking of the horizon, the buzz is that Eli Lilly's next big move could be about a new pill they’re working on. Yeah, they’re not just sticking to injections anymore. That could be a game changer for them, so keep your ears open for updates on that front.

    Alright, that’s the scoop for today! Just remember, I'm here to keep you informed and entertained, but this isn’t financial advice. Stay curious and keep that investing spirit alive! Catch you later!
    続きを読む 一部表示
    1 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません